Chair and CEO Geoff Martha said on the company’s second-quarter earnings call that the medtech giant expects a submission in the first quarter of calendar year 2025.
On the call, Martha said the company is “investing in a strong foundation for future growth.” In addition to the Hugo submission, Medtronic highlighted the launch for its Touch Surgery Live Stream and fast enrollment in hernia and gynecology studies.
“We continue to invest in our Hugo platform,” Martha said. “We’ve completed capturing the necessary data for urology submission and expect to file with the FDA in the first quarter of calendar 2025. We’re also seeing fast enrollment in our next two U.S. indication studies, hernia and gynecology.”
Martha expects to bring ICG fluorescent imaging to Hugo in certain countries soon. He also anticipates adding the company’s LigaSure vessel-sealing technology to Hugo in 2025.
Hugo is a modular, multi-quadrant platform designed for various surgical procedures. It features wristed instruments, 3D visualization and surgical video capture options in Touch Surgery Enterprise. Medtronic first unveiled Hugo in September 2019 as a potential competitor to long-time industry leader Intuitive Surgical.
The company continues to build on the Hugo platform, adding more clinical studies earlier this year to expand its indications to hernia and gynecology. In August, Martha said on the company’s first-quarter earnings call that the company continued its progress on the work needed for an FDA submission Hugo.
“We’re absolutely committed to this … not just being a part of this, but helping to lead it, as we do in spine,” Martha said of surgical robotics.
In September, the company bolstered its surgical robotics efforts with the appointment of Dr. James Porter as chief medical officer of Robotic Surgical Technologies and Digital Technologies.
